“Several” medications marketed by Danish pharmaceutical company Novo Nordisk raised a thyroid cancer safety signal by the European Medicines Agency in May including semaglutide, which is used to manufacture “popular” medications Ozempic and Wegovy, reports Nikolaj Skydsgaard for Reuters. “Such a signal from the EMA does not mean that the medicine is the cause of any reported adverse events,” noted Reuters.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on NVO:
- Novo Nordisk Takes Legal Route to Crack Down on Copycat Drugs
- Novo Nordisk sues spas, clinics selling ‘custom-made’ Ozempic, WSJ reports
- Novo Nordisk price target raised to DKK 1,150 from DKK 950 at Berenberg
- Cantor Fitzgerald biotech/biopharma to hold analyst/industry conference call
- Cantor Fitzgerald biotech/biopharma to hold a luncheon meeting